Eli Lilly’s Emgality gets FDA green light for migraine prevention
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy for adults. The approval marks a significant milestone for Lilly, as Emgality becomes available as a once-monthly, self-administered, subcutaneous injection designed to help prevent migraines. Emgality, a calcitonin gene-related peptide […]